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Abstract
Background: Most group A streptococcal (GAS) vaccine strategies have focused on the surface
M protein, a major virulence factor of GAS. The amino-terminus of the M protein elicits antibodies,
that are both opsonic and protective, but which are type specific. J14, a chimeric peptide that
contains 14 amino acids from the M protein conserved C-region at the carboxy-terminus, offers
the possibility of a vaccine which will elicit protective opsonic antibodies against multiple different
GAS strains. In this study, we searched for J14 and J14-like sequences and the number of their
repeats in the C-region of the M protein from GAS strains isolated from the Northern Thai
population. Then, we examined the bactericidal activity of J14, J14.1, J14-R1 and J14-R2 antisera
against multiple Thai GAS strains.
Results: The emm genes of GAS isolates were sequenced and grouped as 14 different J14-types.
The most diversity of J14-types was found in the C1-repeat. The J14.1 type was the major sequence
in the C2 and C3-repeats. We have shown that antisera raised against the M protein conserved C-
repeat region peptides, J14, J14.1, J14-R1 and J14-R2, commonly found in GAS isolates from the
Northern Thai population, are able to kill GAS of multiple different emm types derived from an
endemic area. The mean percent of bactericidal activities for all J14 and J14-like peptide antisera
against GAS isolates were more than 70%. The mean percent of bactericidal activity was highest
for J14 antisera followed by J14-R2, J14.1 and J14-R1 antisera.
Conclusion: Our study demonstrated that antisera raised against the M protein conserved C-
repeat region are able to kill multiple different strains of GAS isolated from the Northern Thai
population. Therefore, the four conserved "J14" peptides have the potential to be used as GAS
vaccine candidates to prevent streptococcal infections in an endemic area.
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Background
Streptococcus pyogenes or group A streptococcus (GAS) is a
human bacterial pathogen that colonizes the throat or
skin surfaces of the host. GAS infection can lead to a
number of diseases including pharyngitis, impetigo and
necrotising fasciitis. In a small percentage of individuals
that are left untreated or are treated ineffectively with anti-
biotics, streptococcal infections can lead to more serious
illnesses such as rheumatic fever (RF) and rheumatic heart
disease (RHD) which are a significant health concern in
developing countries [1].
Most GAS vaccine strategies have focused on the M pro-
tein, a major virulence factor of GAS. The M protein has
an alpha helical coiled-coil structure comprised of a vari-
able amino terminal domain followed by a set of three
repeat regions called A, B and C-repeats, a cell wall anchor
motif and a stretch of hydrophobic amino acids which are
embedded in the cell membrane. Antibodies to the highly
variable amino terminal region of the M protein have
been shown to be opsonic and protective in murine mod-
els and correlate with protection in humans [2-5]. How-
ever, there are more than 150 recognized emm genotypes
[6] and an increasing number of non-M typeable strains
[7-9]. Therefore, type-specific antibodies are ineffective in
providing broad-spectrum protection against multiple
different GAS strains. Strategies employed to develop a
broad strain coverage GAS vaccine have included the
design of multivalent constructs containing type-specific
M protein sequences [10-13] associated with a particular
disease or geographical region and the identification of
vaccine candidates based on the conserved C-region of the
M protein [14-17].
Many studies have investigated the potential of the M pro-
tein C-repeat region that is conserved among different
GAS strains as a vaccine candidate [14-17]. Using a series
of 15 overlapping peptides spanning the entire M protein
C-region, a peptide LRRDLDASREAKKQVEKALE (p145)
that is recognized by antibodies in the sera of most adults
living in areas of high GAS exposure was identified
[16,18]. The acquisition of these antibodies with age par-
alleled the acquisition of GAS immunity indicating the
potential use of p145 as a vaccine candidate. Human sera
with antibodies to p145 have also been shown to be
opsonic against heterologus GAS strains. Similarly, mice
immunized with p145 elicited antibodies that were
opsonic against GAS [2,3]. However, several studies indi-
cated that p145 contained a T cell epitope shared with
determinants on human cardiac myosin, and keratin in
mouse [19]. In another study [20], J14 (KQAEDKVKAS-
REAKKQVEKALEQLEDRVK), a peptide with minimal B
and T cell epitopes within p145 was identified as a GAS M
protein C-region peptide devoid of potentially deleterious
T cell autoepitopes, but which contained an opsonic B cell
epitope. J14 offers the possibility of a vaccine which will
elicit protective opsonic antibodies against multiple dif-
ferent GAS strains. J14 is a chimeric peptide that contains
14 amino acids from M protein C-region (shown in bold)
and is flanked by yeast-derived GCN4 sequences which
was necessary to maintain the correct helical folding and
conformational structure of the peptide.
From GenBank database search and many studies [3,21],
there are about 60% of GAS that contain J14 sequences,
while the remaining contain J14-like sequences. Although
J14 has the potential to be a vaccine candidate to prevent
streptococcal infection, there are still one-third of M types
that do not contain the J14 sequence but contain J14-like
sequences. This study utilised three peptides, KQAEDKV-
KASREAKKKVEADLAQLEDRVK (J14.1), KQAEDKVKAS-
REAKKQVEKDLAQAEDKVK (J14-R1) and
KQAEDKVKASRAAKKELEAEHQQAEDKVK (J14-R2),
representing commonly occurring J14-like sequences, in
addition to J14, and assessed their ability to elicit broadly
opsonic antibodies following immunization of mice, and
potential as vaccine candidates. It is likely that a vaccine
incorporating J14 and J14-like sequences would be more
beneficial in providing protection against streptococcal
infections covering the majority of GAS M types.
Results and discussion
We searched for J14 and J14-like sequences and the
number of their repeats in the C-terminal region of the M
protein from GAS strains isolated from the Northern Thai
population. Then, we examined the bactericidal activity of
J14, J14.1, J14-R1 and J14-R2 antisera against multiple
Thai GAS strains. This data is important to the develop-
ment of an appropriate vaccine against GAS infection in a
specific endemic population.
Distribution of J14 and J14-like sequences
Twenty different emm types of GAS isolated from Chiang-
Mai, Thailand were included in this study. Emm  types
were analyzed by sequencing the N-terminal region of
emm genes. The C-repeat region of emm genes of these iso-
lates were sequenced to examine the distribution of J14
and J14-like sequences. The majority of the isolates 12/20
(60%) contained three C-repeats. Seven of 20 isolates
(35%) contained two C-repeats. Only one isolate (5%),
ST9, contained a single C-repeat (Table 1).
We found 14 different J14-types which were J14, J14.1,
J14-R1 to J14-R12. The most diversity of J14-types was
found in the C1-repeat which contained 9 different J14-
types (Table 1). The C2-repeat contained 8 different J14-
types with the majority being J14.1 (Table 1). In addition,
J14.1 is also the major sequence within the C3-repeat. J14
was only found in the C3-repeat.BMC Microbiology 2006, 6:71 http://www.biomedcentral.com/1471-2180/6/71
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Although J14 has the potential to be a vaccine candidate
to prevent streptococcal infection, only 5 of 20 (25%)
GAS isolates in our study contained the J14 sequence in
the C-repeat region. Interestingly, the J14.1 sequence was
found with a higher rate, 12 of 20 (60%), than J14. In
addition, we found that J14-R1 and J14-R2 are common
among the remaining J14-types. Therefore, the four "J14"
peptides; J14, J14.1, J14-R1 and J14-R2, are promising
GAS vaccine candidates.
Bactericidal activity of GAS isolates
We have examined the bactericidal activity (% reduction
in CFU) of J14, J14.1, J14-R1 and J14-R2 antisera against
GAS isolates from Chiang Mai, Thailand.
Strong bactericidal activity (>70% reduction) was found
against 75% (15/20), 80% (16/20), 65% (13/20) and
75% (15/20) of GAS isolates when tested with J14, J14.1,
J14-R1 and J14-R2 antisera, respectively (Table 2).
Medium bactericidal activity (50-70% reduction) was
found against 25% (5/20), 15% (3/20), and 10% (2/20)
of GAS isolates when tested with J14, J14-R1 and J14-R2
antisera, respectively (Table 2). Low bactericidal activity
(<50% reduction) was found against 20% (4/20), 20%
(4/20), and 15% (3/20) of GAS isolates when tested with
J14.1, J14-R1 and J14-R2 antisera, respectively (Table 2).
We also compared bactericidal activity of peptide antisera
against GAS containing different numbers of C-repeats.
The mean percent reduction in CFU of isolates with a sin-
gle C-repeat was significantly lower than isolates with two
or three C-repeats (Table 3). This result corresponded to a
study of Vohra et al [21] which found that the mean per-
cent reduction in CFU of isolates with two C-repeats was
statistically lower than strains with three C-repeats.
Recently, Sandin et al. [22] and McArthur et al. [23] have
commented on the capacity of fibrinogen and albumin to
bind to the B- and C-repeats, respectively, causing inhibi-
tion of antibody binding under physiological conditions.
Nevertheless, several studies [18,21,24-26] demonstrated
the binding of anti-C-repeat antibody to GAS isolates,
which are in agreement with our study.
Then, we examined the correlation between the opsoniza-
tion specificity of peptide antisera and J14-types. We
found no correlation between the opsonization ability of
peptide antisera and J14-types contained in the C-repeats.
For example, all J14 peptide antisera showed strong bacte-
Table 1: Sequence of J14 types in the M protein C-repeat region of Thai GAS isolates
Isolate no. emm type* Year of collection Source of isolation C1-repeat C2-repeat C3-repeat
1 ST9 1985 throat - - J14
2 M109 1990 nares - J14.1 J14.1
3 M70 1985 throat - J14.1 J14.1
4 M44 2000 skin - J14-R2 J14.1
5 M66 1985 throat - J14-R5 J14.1
6 M3 - Ref - J14-R1 J14
7 ST1 1985 throat - J14-R9 J14-R6
8 STBSA29 2000 skin - J14-R4 J14-R11
9 M49 1985 skin J14.1 J14.1 J14.1
10 M22 1985 throat J14-R2 J14.1 J14.1
11 ST8 2000 hand J14-R4 J14.1 J14.1
12 M75 1985 skin J14-R6 J14.1 J14.1
13 TR2612 2000 blood J14-R7 J14.1 J14.1
14 ST3 2000 skin J14-R10 J14.1 J14.1
15 ST10 1995 throat J14-R3 J14-R1 J14.1
16 ST6735 2000 leg J14-R5 J14.1 J14-R12
17 M13 - Ref J14-R2 J14-R2 J14-R2
18 M18 - Ref J14-R1 J14-R1 J14
19 M74 1985 throat J14-R3 J14-R3 J14
20 M5 - Ref J14-R3 J14-R8 J14
* emm gene sequencing. Ref, Reference strain from Health Protection Agency Center for Infection, Respiratory and Systemic 
Infection Laboratory, London, UK
J14, ASREAKKQVEKALE. J14.1, ASREAKKKVEADLA. J14-R1, ASREAKKQVEKDLA. J14-R2, ASRAAKKELEAEHQ. J14-R3, ASREAKKQLEAEHQ. 
J14-R4, ASRAAKKELEAKHQ. J14-R5, ASRAAKKDLEAEHQ. J14-R6, ASRAAKKELEANHQ. J14-R7, GSRAAKKELEAKHQ. J14-R8, 
ASREAKKQLEAEQQ. J14-R9, ASREAKKELEANHQ. J14-R10 ASRAAKKGLEAEHQ. J14-R11, ASREANKKVTSELT. J14-R12, ASRAAKKKVEADLA.B
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Table 2: Bactericidal activity* (% reduction in CFU) of J14 peptide antisera against Thai GAS isolates with different emm types
Isolate no. emm type J14 (KALE) J14.1 (ADLA) J14-R1 (KDLA) J14-R2 (AEHQ)
IMS/NMS % reduction IMS/NMS % reduction IMS/NMS % reduction IMS/NMS % reduction
1 ST9 94.5 ± 20.8/200.6 ± 81.8 52.89 ± 10.36 110.5 ± 19.3/200.6 ± 81.8 44.92 ± 9.62 123.5 ± 17.3/200.6 ± 81.8 38.43 ± 8.63 82.9 ± 17.1/200.6 ± 81.8 58.67 ± 8.54
2 M109 34.6 ± 9.5/4025 ± 1753 99.14 ± 0.24 45.1 ± 28.6/4025 ± 1753 98.88 ± 0.71 38.3 ± 26.4/4025 ± 1753 99.05 ± 0.66 25.6 ± 7.8/4025 ± 1753 99.36 ± 0.19
3 M70 215.5 ± 136.5/5171 ± 1916 95.83 ± 2.64 123.9 ± 101.9/5171 ± 1916 97.60 ± 1.97 217.1 ± 112.9/5171 ± 1916 95.80 ± 2.18 152.5 ± 55.2/5171 ± 1916 97.05 ± 1.07
4 M44 10.5 ± 6.4/297.6 ± 140 96.47 ± 2.16 14.1 ± 7.5/297.6 ± 140 95.25 ± 2.52 63 ± 22.7/297.6 ± 140 78.83 ± 7.61 3.8 ± 3.1/297.6 ± 140 98.72 ± 1.03
5 M66 31.8 ± 9.5/117 ± 129 72.86 ± 8.11 11.2 ± 8.3/117 ± 129 90.46 ± 7.05 18.7 ± 11.1/117 ± 129 84.05 ± 9.45 5.2 ± 2.6/117 ± 129 95.58 ± 2.19
6 M3 102.9 ± 43.8/1514 ± 532 93.21 ± 2.89 268.4 ± 69.7/1514 ± 532 82.28 ± 4.60 634.3 ± 187.7/1514 ± 532 58.11 ± 12.4 30.4 ± 11.4/1514 ± 532 97.99 ± 0.75
7 ST1 7.5 ± 2.3/20.8 ± 8.2 63.94 ± 11.02 4.1 ± 1.5/20.8 ± 8.2 80.17 ± 7.18 10.2 ± 2.8/20.8 ± 8.2 51.12 ± 13.24 11.3 ± 1.3/20.8 ± 8.2 45.51 ± 6.05
8 STBSA29 16.4 ± 9.7/59.9 ± 44.9 72.66 ± 16.16 15.0 ± 3.5/59.9 ± 44.9 74.96 ± 5.84 29.2 ± 6.3/59.9 ± 44.9 51.31 ± 10.44 7.8 ± 4.5/59.9 ± 44.9 86.92 ± 7.57
9 M49 25.9 ± 14.8/278.5 ± 251 90.99 ± 5.15 31.6 ± 16.2/278.5 ± 251 89.01 ± 5.64 24.8 ± 22.1/278.5 ± 251 91.39 ± 7.68 22.5 ± 16.3/278.5 ± 251 92.17 ± 5.67
10 M22 52.9 ± 44.4/3437 ± 1099 98.46 ± 1.29 155.4 ± 66.7/3437 ± 1099 95.48 ± 1.94 246.1 ± 66.8/3437 ± 1099 92.84 ± 1.94 24.2 ± 11.6/3437 ± 1099 99.30 ± 0.34
11 ST8 391.3 ± 55.0/2336 ± 381 83.25 ± 2.36 663.2 ± 124.9/2336 ± 381 71.60 ± 5.35 485.8 ± 59.0/2336 ± 381 79.20 ± 2.52 576.8 ± 26.4/2336 ± 381 75.31 ± 1.13
12 M75 125.3 ± 75.1/1661 ± 1014 92.46 ± 4.52 191.2 ± 48.9/1661 ± 1014 88.49 ± 2.94 119 ± 79.1/1661 ± 1014 92.84 ± 4.77 75.9 ± 28.2/1661 ± 1014 95.43 ± 1.70
13 TR2612 394.3 ± 34.4/7776 ± 3043 94.93 ± 0.44 606.8 ± 163.4/7776 ± 3043 92.20 ± 2.10 212.6 ± 21.1/7776 ± 3043 97.27 ± 0.27 440.6 ± 69.2/7776 ± 3043 94.33 ± 0.89
14 ST3 3.0 ± 1.2/14.7 ± 8.3 79.59 ± 7.86 2.0 ± 1.1/14.7 ± 8.3 86.39 ± 7.35 1.1 ± 1.3/14.7 ± 8.3 92.35 ± 8.95 6.0 ± 2.6/14.7 ± 8.3 59.18 ± 17.78
15 ST10 22.2 ± 9.6/1284 ± 961 98.27 ± 0.75 82.6 ± 31.6/1284 ± 961 93.56 ± 2.46 52.6 ± 22.0/1284 ± 961 95.90 ± 1.71 61.8 ± 14.8/1284 ± 961 95.19 ± 1.15
16 ST6735 30.5 ± 4.5/87.5 ± 47 65.14 ± 5.13 75.7 ± 13.0/87.5 ± 47 13.52 ± 14.84 49.5 ± 6.5/87.5 ± 47 43.43 ± 7.43 51.0 ± 7.7/87.5 ± 47 41.71 ± 8.80
17 M13 72.6 ± 31.2/1130 ± 571 93.57 ± 2.76 196.5 ± 27.0/1130 ± 571 82.61 ± 2.39 320.3 ± 124.4/1130 ± 571 71.65 ± 11.0 46.6 ± 25.0/1130 ± 571 95.87 ± 2.21
18 M18 386.0 ± 68.2/2113 ± 650 81.73 ± 3.23 362.1 ± 157.9/2113 ± 650 82.86 ± 7.47 215.3 ± 195.4/2113 ± 650 89.81 ± 9.25 124.2 ± 54.2/2113 ± 650 94.12 ± 2.57
19 M74 270.8 ± 75.2/664.5 ± 228 59.24 ± 11.32 429.8 ± 83.4/664.5 ± 228 35.31 ± 12.55 383 ± 60.6/664.5 ± 228 42.36 ± 9.12 368.5 ± 42.9/664.5 ± 228 44.54 ± 6.45
20 M5 375.6 ± 47.4/1092 ± 154.9 65.60 ± 4.34 608.5 ± 24.2/1092 ± 154.9 44.28 ± 2.21 645.7 ± 54.3/1092 ± 154.9 40.87 ± 4.97 303.2 ± 44.4/1092 ± 
154.9
72.23 ± 4.07
* The value is an average of experiment done in quadruplicate.
IMS/NMS: mean CFU in immune serum ± SD/mean CFU in normal serum ± SDBMC Microbiology 2006, 6:71 http://www.biomedcentral.com/1471-2180/6/71
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ricidal activity (>70% reduction) against isolates 2 and 3
having only J14.1 with two C-repeats and isolate 9 also
having only J14.1 but with three C-repeats.
These data indicate that these four peptides, J14, J14.1,
J14-R1 and J14-R2, have the potential to be used as GAS
vaccine candidates to prevent streptococcal infections.
For further study towards the development of a broad
strain protective GAS vaccine, it may be possible to use a
strategy designed to assemble all four J14 peptides into a
single construct [27]. This would have several advantages,
including inducing a heterologous opsonic immune
response and also providing protection against challenge
with many different GAS strains [4]. One such technology
is the lipid core peptide (LCP) technology [25,28] which
has been used to incorporate up to four different peptides
into a single LCP vaccine construct [29]. This system also
incorporates the carrier and adjuvant into the vaccine and
has the potential for the development of self-adjuvanting
multi-antigen component vaccines for human application
[25,30].
Conclusion
Our study demonstrated that antisera raised against the M
protein conserved C-repeat region are able to kill multiple
different GAS strains isolated from the Northern Thai
population. Therefore, the four conserved "J14" peptides
have the potential to be used as GAS vaccine candidates to
prevent streptococcal infections in an endemic area.
Methods
Bacteria
GAS strains used in this study were isolated from the nor-
mal population and patients with sore throat, rheumatic
heart disease or impetigo in 1985, 1990, 1995, and 2000
from Chiang Mai, Thailand.
DNA isolation and PCR
DNA was isolated from GAS based on the method previ-
ously described [8,31]. The sense primer (CAGTAT-
TCGCTTAGAAAATT AAAA) is derived from the conserved
leader sequence of the emm  gene [32]. The antisense
primer for OF-positive emm gene, P49 (TTGGGATCCT-
GCTGATCTT GAACGGTTAGC), is derived from the con-
served region of the membrane anchor [33]. The antisense
primer for OF-negative emm  gene, P6 (TGCGGATC-
CAGCTGTT GCCATAACAGTAAG), is derived from the
conserved region of the proline/glycine rich region [33].
The PCR conditions were 94°C for 1 minute, 35 cycles at
94°C for 30 second, 45°C for 30 second, and 72°C for 2
minutes, ending with 72°C for 10 minutes.
Searching for J14 and J14-like sequences and the number 
of their repeats in the conserved carboxy terminal segment 
of the M protein
The PCR products of emm gene were sequenced using the
ABI Dye Terminator Cycle Sequencing Ready Reaction Kit
following the manufacturer's instructions (The Perkin-
Elmer Corporation) and determined by an ABI 310 auto-
mated sequencer (The Perkin-Elmer Corporation). The
obtained DNA sequences of the conserved carboxy termi-
nal segment of the M protein were deduced into an amino
acid sequence and then searched for J14 sequence or J14-
like sequences. The number of their repeats was recorded.
Peptides
J14, J14.1, J14-R1 and J14-R2, containing 29 amino acid
sequences KQAEDKVKASREAKKQVEKALEQLEDRVK,
KQAEDKVKASREAKKKVEADLAQLEDRVK, KQAEDKV-
KASREAKKQVEKDLAQAEDKVK and KQAEDK VKAS-
RAAKKELEAEHQQAEDKVK, respectively, were
synthesized by the "tea-bag" method. Purity was checked
by HPLC. Peptides were dissolved in water at a concentra-
tion of 10 mg/ml and kept at -20°C until used.
Antisera
Antisera to J14, J14.1, J14-R1 and J14-R2 peptides were
raised in B10.BR mice. Mice, eight per group, were immu-
nized subcutaneously at the tail base with 30 μg of pep-
tide emulsified in complete Freund's adjuvant (a total of
50  μl was administered). Mice were given subsequent
booster injections at intervals of 7 days with 3 μg peptide
dissolved in PBS for 5 boosts. Prior to boosting, mice were
bled and sera isolated were kept at -20°C until used. Anti-
body production was assessed by ELISA. Sera showing
titer more than 6400 were pooled and used in indirect
bactericidal assays to assess their ability to opsonize GAS.
Table 3: Bactericidal activity (mean % reduction in CFU) of J14 peptide antisera against Thai GAS isolates with different numbers of M 
protein C-repeats.
Isolate no. Number of C-repeat Bactericidal activity (% reduction)
J14 (KALE) J14.1 (ADLA) J14-R1 (KDLA) J14-R2 (AEHQ)
1 single 52.89 ± 10.36* 44.91 ± 9.62* 38.43 ± 8.63* 58.67 ± 8.54*
2–8 two 84.87 ± 14.49 88.51 ± 9.41 74.04 ± 20.49 88.73 ± 19.52
9–20 three 83.60 ± 13.73 72.94 ± 26.88 77.49 ± 22.44 79.95 ± 21.07
* Significantly less (P < 0.05) compared to isolate numbers 2–8 and 9–20.BMC Microbiology 2006, 6:71 http://www.biomedcentral.com/1471-2180/6/71
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ELISA
Peptides were diluted to 5 μg/ml in carbonate-bicarbo-
nate buffer, pH 9.6, and coated onto microtiter plates in a
volume of 100 μl per well overnight at 4°C. Excess antigen
was removed and the wells were blocked with 200 μl of
5% skim milk in PBS-Tween 20 for 1.5 hr at 37°C. Plates
were washed five times with PBS-Tween 20. Serum dilu-
tions prepared in 0.5% skim milk in PBS-Tween 20 were
added and incubated for 1.5 hr at 37°C. Plates were
washed five times with PBS-Tween 20 and incubated with
peroxidase conjugated sheep-anti-mouse IgG at a dilution
of 1:3000 in 0.5% skimmed milk for 1.5 hr at 37°C. Plates
were washed five times with PBS-Tween 20. 100 μl of o-
phenylenediamine (OPD) substrate was added and incu-
bated for 30 min. The optical density was measured at 450
nm in an ELISA plate reader. The highest dilution that
gave an O.D. 3× higher than those of the average of con-
trol wells containing normal mouse serum at the same
dilution was defined as the titer.
Indirect bactericidal assay
GAS isolates were cultured overnight in Todd-Hewitt
broth at 37°C and diluted to 10-5 dilution in sterile NSS
and kept on ice. Fifty μl of the bacterial dilution were
plated out in duplicate using the pour plate method and
incubated at 37°C for 24 hrs. The numbers of colonies
were counted and the colony forming units (CFUs) from
these plates were determined as the inoculum size. Fifty μl
of the bacterial dilution were also mixed with 50 μl of
serum (normal mouse or immune mouse) and then 400
μl of non-opsonic heparinized human donor blood was
added. The mixtures were incubated end-over-end at
37°C for 3 hrs, and then 50 μl were plated out in duplicate
using the pour plate method. CFUs were counted after 24
hrs of incubation. Bactericidal activity of immune sera (%
reduction in mean CFU) was calculated as: 1-[mean CFUs
in the presence of immune mouse sera/mean CFUs in the
presence of normal mouse sera] × 100. Blood and bacte-
rial controls were included with each isolate of GAS. Each
isolate of GAS was done in quadruplicate.
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